// App-Quantinova.ai

: The approach consortium: a 2-year, European, cohort study to describe, validate, and predict phenotypes of knee osteoarthritis by use of clinical, imaging, and biochemical markers

Researchers

Presenter

  • E.M. van Helvoort

Principal Investigators

  • W.E. van Spil

  • A.C. Marijnissen

  • P.M. Welsing

  • A.C. Bay-Jensen

  • L. Hussaarts

  • C. Ladel

  • A. Lalande

  • J. Larkin

  • M.C. Levesque

  • J. Loughlin

  • A. Mobasheri

  • L. Paolozzi

  • F. Petit-Dop

  • H. Weinans

  • F.P. Lafeber

Medical Centers

  • Dept. of Rheumatology & Clinical Immunology, Univ. Med. Ctr. Utrecht, Utrecht, Netherlands

  • Nordic BioSci. Biomarkers and Res., Herlev, Denmark

  • Lygature,Utrecht,Netherlands

  • Merck KGaA, Darmstadt, Germany

  • Institut de Recherches Internationales Servier, Suresnes, France

  • GlaxoSmithKline, King of Prussia, PA.

  • AbbVie Inc., Worcester MA, USA

  • Inst. of Genetic Med., Newcastle Univ., Newcastle, United Kingdom

  • Faculty of Hlth. and Med. Sci., Univ. of Surrey, Guildford, United Kingdom

Locations

  • Netherlands

  • Denmark

  • Germany

  • France

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

Disease

  • Knee osteoarthritis

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Prospective

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved